Express | Jianzhi T-cell therapy treatment of two major obstacles to solid tumors, Xinrui plans to 150 million US dollars IPO

▎The content team editor of WuXi AppTec today, Lyell Immunopharma (hereinafter referred to as Lyell), which is committed to developing innovative T-cell therapies for the treatment of solid tumors, submitted relevant documents to regulatory agencies and plans to log on to Nasdaq and raise US$150 million in funding.

Immune cell therapy represented by CAR-T therapy has made significant progress in the treatment of hematological cancers.
However, there are still multiple challenges in the treatment of solid tumors.

Lyell was co-founded by Dr.
Richard Klausner, the former head of the National Cancer Institute and a senior expert in the field of cell therapy, with the aim of developing solid tumor T cells with "curing" potential by "reprogramming" T cells therapy.

▲Dr.
Richard Klausner, CEO of Lyell, shared his insights on cell therapy development at WuXi AppTec Global Forum 2020 Related reading: Saying goodbye to the "Stone Age" of cell therapy | WuXi AppTec Global Forum The company believes that T cell therapy is treating solid tumors There are two major obstacles: one is the exhaustion of T cells, which leads to the loss of the function of killing tumor cells; the other is that the stem cell characteristics of T cells are not durable enough, which leads to the limited ability of continuous proliferation and renewal of T cell therapy.

In response to these two obstacles, Lyell has developed two proprietary technology platforms.
The technology platform called Gen-R overcomes T cell depletion by reprogramming T cells in vitro.

In preclinical experiments, Gen-R restored the anti-cancer activity of T cells in solid tumor models by optimizing the overexpression of c-JUN.

The company's Epi-R technology platform uses epigenetic reprogramming technology to create a unique T cell population with durable stem cell characteristics.

Using these two platforms, the company’s R&D pipeline has 4 cell therapies under investigation.
The main CAR-T therapy LYL797 is a CAR-T therapy targeting the ROR1 antigen.
This therapy also adds a Optimized safety switch for epidermal growth factor receptor (EGFR).

It can be used to treat patients with non-small cell lung cancer, triple-negative breast cancer and other types of cancer that express ROR1.

▲Lyell’s cell therapy R&D pipeline (picture source: Lyell’s official website) Since its establishment, Lyell has not only reached a R&D cooperation with Orca Bio, which has precise purification T cell technology, but also built its own cell therapy production center.

The prospectus pointed out that the company's research cell therapy is expected to enter the clinical development stage in 2022.

Reference: [1] FORM S-1 REGISTRATION STATEMENT.
Retrieved May 26, 2021, from Lyell Therapeutics.
Retrieved May 26, 2021, from https://lyell.
com/ Note: This article aims to introduce the progress of medical and health research, and is not a treatment plan recommendation.

If you need guidance on the treatment plan, please go to a regular hospital for treatment.